Phase III Trial Shows Pembrolizumab-Olaparib Benefits for Ovarian Cancer
A recent Phase III trial reveals that the combination of pembrolizumab and olaparib significantly extends progression-free survival in advanced ovarian cancer patients without BRCA mutations.
The ENGOT-OV43 trial involved 1,367 patients with advanced ovarian cancer.
Pembrolizumab combined with olaparib reduced the risk of disease progression by 37% in patients with a PD-L1 CPS of at least 10.
Adverse events were more frequent in the pembrolizumab-olaparib group, highlighting the need for careful monitoring.
In a significant advancement for ovarian cancer treatment, a Phase III clinical trial has demonstrated that the combination of pembrolizumab and olaparib can notably prolong progression-free survival in patients diagnosed with advanced BRCA non-mutated ovarian cancer. This study, known as the ENGOT-OV43/GOG-3036/KEYLYNK-001 trial, involved 1,367 participants across 22 countries, focusing on individuals with stage III–IV epithelial ovarian, primary peritoneal, or fallopian tube cancer.
The trial's design included a randomized, double-blind approach where patients received either pembrolizumab combined with chemotherapy followed by maintenance therapy of pembrolizumab and olaparib, or other control regimens. The median age of participants was 61, and the study aimed to explore the efficacy of combining immunotherapy with PARP inhibition, particularly for patients lacking BRCA mutations, who traditionally have fewer treatment options.
Results from the first interim analysis, conducted after a median follow-up of 30.1 months, indicated that the pembrolizumab-olaparib combination significantly improved progression-free survival for patients with a PD-L1 combined positive score (CPS) of at least 10. Specifically, this group experienced a 37% reduction in the risk of disease progression or death compared to the control group. The overall intention-to-treat population also showed a 32% reduction in risk, emphasizing the treatment's potential effectiveness.
However, the combination therapy was associated with a higher incidence of adverse events. Grade 3 or worse treatment-related side effects were reported in 66% of patients receiving pembrolizumab-olaparib, compared to 56% in the pembrolizumab-only group and 51% in the control group. The most frequently observed severe events included neutropenia and anemia, with treatment-related deaths occurring in both the pembrolizumab-olaparib and pembrolizumab groups.
The findings suggest that while pembrolizumab combined with olaparib could serve as a promising first-line treatment for advanced BRCA non-mutated epithelial ovarian cancer, the increased toxicity necessitates careful consideration. Further analysis and monitoring will be essential as researchers continue to evaluate the long-term benefits and risks associated with this treatment strategy.
